Study of VNRX-5133 in combination with a clinically validated broad spectrum beta-lactam for bacterial infections.
Phase of Trial: Phase II/III
Latest Information Update: 08 Jan 2018
At a glance
- Drugs VNRX 5133 (Primary) ; Beta-lactams
- Indications Bacterial infections
- Focus Registrational; Therapeutic Use
- 08 Jan 2018 According to VenatoRx Pharmaceuticals pipeline, phase of this trial is phase II/III. (www.venatorx.com/pipeline/)
- 08 Jan 2018 New trial record
- 03 Jan 2018 According to the VenatoRx Pharmaceuticals media release, company will start this pivotal registration trial in 2018.